<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01436539</url>
  </required_header>
  <id_info>
    <org_study_id>Ditan-2011-01</org_study_id>
    <nct_id>NCT01436539</nct_id>
  </id_info>
  <brief_title>Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients</brief_title>
  <official_title>A Multi-center, Open Label, Randomized Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Capsule Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jun Cheng</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Cosunter Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the effects and safety of Adefovir Dipivoxil plus
      polyene phosphatidylcholine compared to Adefovir Dipivoxil alone in patients with chronic
      hepatitis B.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportions of subjects with histological response in treatment and control group.</measure>
    <time_frame>at week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportions of subjects in each group who achieve: HBV DNA &lt; 300 copies/mL</measure>
    <time_frame>at week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean log10 reduction from baseline in HBVDNA</measure>
    <time_frame>at week 12, 24, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT normalization rate and range</measure>
    <time_frame>at week 12 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver stiffness values reduction from baseline by Fibroscan</measure>
    <time_frame>at week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg loss and HBe seroconversion</measure>
    <time_frame>at week 12 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg loss and HBs seroconversion</measure>
    <time_frame>at week 12 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in symptoms score</measure>
    <time_frame>at week 12, 24 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>up to 60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of serious adverse events</measure>
    <time_frame>up to 60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of discontinuations from study drug due to adverse events or laboratory abnormalities.</measure>
    <time_frame>up to 60 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Adefovir Dipivoxil and polyene phosphatidylcholine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adefovir Dipivoxil 10 mg once daily for 48 weeks plus Polyene phosphatidylcholine (PPC) 456 mg three times per day for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adefovire Dipivoxil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adefovir Dipivoxil 10 mg once daily for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir Dipivoxil and polyene phosphatidylcholine</intervention_name>
    <description>Adefovir Dipivoxil 10 mg once daily for 48 weeks plus Polyene phosphatidylcholine (PPC) 456 mg three times per day for 48 weeks</description>
    <arm_group_label>Adefovir Dipivoxil and polyene phosphatidylcholine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir Dipivoxil</intervention_name>
    <description>Adefovir Dipivoxil 10 mg once daily for 48 weeks</description>
    <arm_group_label>Adefovire Dipivoxil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females between the age of 18 to 65 years with chronic hepatitis B.

          -  HBsAg positive for a minimum of 6 months.

          -  HBV DNA ≥4 log10 copies/ml, and ≤ 6 log10 copies/mL

          -  Alanine aminotransferase (ALT) ≥ 2 times the upper limit of normal(ULN) and ≤10 times
             ULN, and documented ALT abnormal within 6 month prior to the study screening.

          -  Had a liver biopsy performed within 6 months prior to randomization and has readable
             biopsy slides or agrees to have a biopsy performed prior to entry.

          -  Willing and able to provide written informed consent.

        Exclusion Criteria:

          -  Received any nucleoside, nucleotide or interferon therapy within 6 months prior to the
             screening.

          -  Previous treatment with lamivudine, adefovir, entecavir or telbivudine and occurred
             viral breakthrough or genotype resistance.

          -  Received immunosuppressive agents or other immunoregulates (including
             thymosin),systemic cytotoxic drugs, other antiviral agents including Chinese herb
             medicine within 6 months prior to the screening.

          -  Active alcohol intake( more than 20g/d for female or more than 30g/d for male) or drug
             abuse within 1 year prior to screening. Alcohol or drug abuse considered by the
             investigator to be sufficient to hinder compliance with treatment, participation in
             the study or interpretation of results.

          -  ALT is greater than 10 times ULN at screening or has the history of transient
             decompensated liver disease due to acute exacerbation.

          -  Any of the laboratory test at screening as the following :

               -  serum creatinine &gt; 1.5 mg/dl ;

               -  prothrombin time ≥ 4 seconds prolonged or PTA &lt;60%;

               -  serum albumin&lt;32 g/L;

               -  serum bilirubin&gt;3.0mg/dL;

               -  Hemoglobin&lt;11g/dL(males) or &lt;10 g/dL(females), white blood cells count&lt;3.5 x
                  10^9/L, absolute neutrophil count &lt;1.5 x 10^9/L, platelets&lt;80 x 10^9/L.

          -  Patient is coinfected with HCV, HDV or HIV.

          -  Hepatocellular carcinoma (HCC), or the presence of a mass on imaging studies of the
             liver that is suggest of HCC, or an alpha-fetoprotein (AFP)&gt; 500ng/mL.

          -  Decompensated liver disease as defined by serum bilirubin &gt;3mg/dL, prothrombin time≥ 4
             seconds prolonged, a serum albumin&lt;32g/L, or a history of ascites, variceal bleeding
             or hepatic encephalopathy.

          -  Presence of other causes of liver disease (i.e.alcoholic liver disease,autoimmune
             hepatitis, hemochromatosis, Wilson disease, nonalcoholic steatohepatitis,
             alpha-1anti-trypsin deficiency).

          -  Any serious or active medical or psychiatric illnesses other than hepatitis B which,
             in the opinion of the investigator, would interfere with patient treatment, assessment
             or compliance with the protocol. This would include, may not limit to, renal, cardiac,
             pulmonary, vascular, neurogenic, digestive, metabolic (diabetes, thyroid disorders,
             adrenal disease), immunodeficiency disorders, active infection or cancer.

          -  BMI≥30.

          -  Patient is pregnant or breast-feeding.

          -  Planned for liver transplantation or previous liver transplantation.

          -  Need take hepatotoxic drugs (e.g.,dapsone, erythromycin, fluconazole, rifampin, etc)
             and nephrotoxic drugs (e.g., NSAIDs, aminoglycosides, amphotericin B, foscarnet, etc.)
             for long time.

          -  History of hypersensitivity to nucleoside analogues.

          -  Previous (or planned) participation in an investigational trial involving
             administration of investigational compound within 12 weeks prior to the study
             screening.

          -  Poor compliance of the patient considered by investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Ditan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100015</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jun Cheng, post doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2011</study_first_submitted>
  <study_first_submitted_qc>September 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2011</study_first_posted>
  <last_update_submitted>September 16, 2011</last_update_submitted>
  <last_update_submitted_qc>September 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Capital Medical University</investigator_affiliation>
    <investigator_full_name>Jun Cheng</investigator_full_name>
    <investigator_title>Vice president</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
    <mesh_term>Polyene phosphatidylcholine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

